New diabetes treatment

29 July 2015

Xultophy, a combination of the long-acting (basal) insulin degludec and the glucagon-like peptide 1 receptor agonist liraglutide (IDegLira), is now available.

Xultophy is indicated for adults with type 2 diabetes and is combined with oral glucose-lowering drugs when these alone or when combined with basal insulin do not adequately control glycaemia.

Read more →